The Anticancer Action of Lymphotoxin

  • Charles H. Evans
  • Janet H. Ransom
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)


Study of the mechanisms of natural immunity at the target cell level possessing the potential to prevent and intervene to modulate the development of carcinogenesis has identified lymphotoxin to be a major component (Evans et al., 1983). Lymphotoxin anticancer activities include: (1) cancer prevention measured by irreversible inhibition of chemical carcinogen or radiation transformation of syngeneic Syrian hamster cells in vitro (Evans and DiPaolo, 1981) or in a combined in vivo-in vitro transplacental carcinogenesis assay (Ransom et al., 1982b, 1983a); (2) cytostasis assessed by reversible growth inhibition of allogeneic or syngeneic tumor cells (Evans and Heinbaugh, 1981; Evans et al., 1983); (3) cytolysis indicated by radionuclide release from allogeneic or syngeneic tumor cells (Evans and Heinbaugh, 1981); and (4) cytoreductive stimulating activity demonstrated by enhanced sensitivity of lymphotoxin-treated tumor cells to natural killer cell cytolysis (Ransom and Evans, 1982, 1983).


Natural Killer Cell Anticancer Action L929 Cell Syrian Hamster Cytolytic Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aggarwal, B., Moffat, B., and Harkins, R., 1983, Purification and characterization of lymphotoxin from the human lymphoblastoid cell line 1788, in: Interleukins, Lymphokines, and Cytokines (J.J. Oppenheim, S. Cohen, and M. Landy, eds.), pp. 521–526, Academic Press, New York.Google Scholar
  2. DiPaolo, J. A., Evans, C. H., DeMarinis, A. J., and Doniger, J., 1984, Inhibition of radiation initiated and promoted transformation of Syrian hamster embryo cells by lymphotoxin. Cancer Res. 44: 1465–1471.PubMedGoogle Scholar
  3. Evans, C. H., 1982, Lymphotoxin—An immunologic hormone with anticarcinogenic and antitumor activity, Cancer Immunol. Immunother. 12:181–190.CrossRefGoogle Scholar
  4. Evans, C. H., 1983, Lymphokines, homeostasis, and carcinogenesis, J. Natl. Cancer Inst. 71:253–257.PubMedGoogle Scholar
  5. Evans, C. H., and DiPaolo, J. A., 1975, Neoplastic transformation of guinea pig fetal cells in culture induced by chemical carcinogens, Cancer Res. 35:1035–1044.PubMedGoogle Scholar
  6. Evans, C. H., and DiPaolo, J. A., 1981, Lymphotoxin: An anticarcinogenic lymphokine as measured by inhibition of chemical carcinogen or ultraviolet irradiation induced transformation of Syrian hamster cells, Int. J. Cancer 27:45–49.PubMedCrossRefGoogle Scholar
  7. Evans, C. H., and Heinbaugh, J. A., 1981, Lymphotoxin cytotoxicity, a combination of cytolytic and cytostatic cellular responses, Immunopharmacology 3:347–359.PubMedCrossRefGoogle Scholar
  8. Evans, C. H., Cooney, A. M., and DiPaolo, J. A., 1975, Colony inhibition mediated by nonimmune leukocytes in vitro as indices of tumorigenicity of guinea pig cultures transformed by chemical carcinogens, Cancer Res. 35:1045–1052.PubMedGoogle Scholar
  9. Evans, C. H., Heinbaugh, J. A., and DiPaolo, J. A., 1983, Comparative effectiveness of lymphotoxin anti-carcinogenic and tumor cell growth inhibitory activities, Cell. Immunol. 76:295–303.PubMedCrossRefGoogle Scholar
  10. Fuhrer, J. P., and Evans, C. H., 1983, The anticarcinogenic and tumor growth inhibitory activities of lymphotoxin are associated with altered membrane glycoprotein synthesis, Cancer Lett. 19:283–292.PubMedCrossRefGoogle Scholar
  11. Ransom, J. H., and Evans, C. H., 1982, Lymphotoxin enhances the susceptibility of neoplastic and preneoplastic cells to natural killer cell mediated destruction, Int. J. Cancer 29:451–458.PubMedCrossRefGoogle Scholar
  12. Ransom, J. H., and Evans, C. H., 1983, Molecular and biological characterization of anti-carcinogenic and tumor cell growth-inhibitory activities of Syrian hamster lymphotoxin, Cancer Res. 43:5222–5227.PubMedGoogle Scholar
  13. Ransom, J. H., Rundell, J. O., Heinbaugh, J. A., and Evans, C. H., 1982a, Biological and physico-chemical characterization of keyhole limpet hemocyanin-induced guinea pig lymphotoxin, Cell. Immunol. 67:1–13.CrossRefGoogle Scholar
  14. Ransom, H.H., Evans, C. H., and DiPaolo, J. A., 1982b, Lymphotoxin prevention of diethylnitrosamine carcinogenesis in vivo, J. Natl. Cancer Inst. 69:741–744.Google Scholar
  15. Ransom, J. A., Evans, C. H., Jones, A. E., Zoon, R. A., and DiPaolo, J. A., 1983a, Control of the carcinogenic potential of 99mtechnetium by the immunologic hormone lymphotoxin, Cancer Immunol. Immunother. 15:126–130.CrossRefGoogle Scholar
  16. Ransom, J. H., Pintos, C., and Evans, C. H., 1983b, Lymphotoxin amplification of tumor growth inhibition is specific for natural killer cells not macrophages, Int. J. Cancer 32:93–97.CrossRefGoogle Scholar
  17. Rundell, J. O., and Evans, C. H., 1981, Species specificity of guinea pig and human lymphotoxin colony inhibitory activity, Immunopharmacology 3:9–18.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Charles H. Evans
    • 1
  • Janet H. Ransom
    • 1
  1. 1.Tumor Biology Section, Laboratory of Biology, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations